Toxic thyroid adenoma

Following treatment, thyroid function tests (TFTs) should be monitored along with clinical exam. There are no specific guidelines for the monitoring schedule. One approach after I-131 therapy is to monitor at 2 and 6 weeks; 3, 6, and 12 months; and then yearly.

Baseline CBC with differential for any patient taking antithyroid drugs is reasonable, but there are no specific guidelines, and no demonstrated benefit to routine follow-up CBC. Immediate patient reporting of any symptoms of infection is important because agranulocytosis may occur unpredictably. CBC with differential should be checked in any patient who develops fever, rash, or pharyngitis while taking antithyroid drugs.